METHODS AND COMPOSITIONS USING LISTERIA FOR ENHANCING IMMUNOGENICITY BY PRIME BOOST
Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.
1 - 49 . (canceled)
50 . A method for immunizing a mammal to induce an immune response to a cancer antigen, comprising:
immunizing the mammal using a prime-boost regimen, wherein the regimen comprises
(i) administering to the mammal an effective amount of a prime dose of a recombinant adenovirus vector expressing a nucleic acid that encodes an expressible, immunologically active portion of the cancer antigen; and
(ii) following the prime dose administration, administering to the mammal an effective amount of a boost dose of a vaccine comprising an attenuated Listeria that encodes the expressible, immunologically active portion of the cancer antigen.
51 . A method according to claim 50 , wherein the recombinant adenovirus vector is administered intratumorally or peritumorally.
52 . A method according to claim 50 , wherein the recombinant adenovirus vector is administered intravenously.
53 . A method according to claim 50 , wherein the attenuated Listeria is administered intravenously.
54 . A method according to claim 51 , wherein the attenuated Listeria is administered intravenously.
55 . A method according to claim 52 , wherein the attenuated Listeria is administered intravenously.
56 . A method according to claim 50 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D.
57 . A method according to claim 51 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D.
58 . A method according to claim 52 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D.
59 . A method according to claim 53 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D.
60 . A method according to claim 54 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D.
61 . A method according to claim 55 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D.
62 . A method according to claim 56 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D.